185 related articles for article (PubMed ID: 7609862)
1. Suspension therapy in acute schizophrenia. Clinical and neuroendocrine/biochemical effects of abrupt discontinuation of neuroleptic medication.
Kuhs H; Folkerts H
Neuropsychobiology; 1995; 31(3):135-45. PubMed ID: 7609862
[TBL] [Abstract][Full Text] [Related]
2. Suspension of neuroleptic therapy in acute schizophrenia.
Kuhs H; Eikelmann B
Pharmacopsychiatry; 1988 Jul; 21(4):197-202. PubMed ID: 2905064
[TBL] [Abstract][Full Text] [Related]
3. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
Nagaoka S; Iwamoto N; Arai H
Biol Psychiatry; 1997 Apr; 41(8):857-64. PubMed ID: 9099412
[TBL] [Abstract][Full Text] [Related]
4. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects.
Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U
Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612
[TBL] [Abstract][Full Text] [Related]
5. Increments in plasma homovanillic acid concentrations after neuroleptic discontinuation are associated with worsening of schizophrenic symptoms.
Khan RS; Amin F; Powchik P; Knott P; Goldstein M; Apter S; Kerman B; Jaff S; Davidson M
Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(6):879-84. PubMed ID: 1980541
[TBL] [Abstract][Full Text] [Related]
6. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
[TBL] [Abstract][Full Text] [Related]
7. Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays.
Smith RC; Baumgartner R; Misra CH; Mauldin M; Shvartsburd A; Ho BT; DeJohn C
Arch Gen Psychiatry; 1984 Nov; 41(11):1044-9. PubMed ID: 6497566
[TBL] [Abstract][Full Text] [Related]
8. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation.
Davidson M; Kahn RS; Powchik P; Warne P; Losonczy MF; Kaminsky R; Apter S; Jaff S; Davis KL
Arch Gen Psychiatry; 1991 Jan; 48(1):73-6. PubMed ID: 1670618
[TBL] [Abstract][Full Text] [Related]
9. Prediction of response to haloperidol in schizophrenia: neuroendocrine, neuromorphological and clinical variables.
Mauri MC; Vita A; Giobbio GM; Ferrara A; Dieci M; Bitetto A; Altamura AC
Int Clin Psychopharmacol; 1994; 9(1):3-7. PubMed ID: 8195579
[TBL] [Abstract][Full Text] [Related]
10. [Psychopathologic changes in chronic schizophrenic patients following withdrawal of neuroleptics: relation to therapeutic, neuroendocrine and computer tomography variables].
Albus M; Naber D; Ackenheil M; Bürke H; Müller-Spahn F; Münch U; Reinertshofer T; Schmidt-Vanderheyden W; Weber G; Wissmann J
Fortschr Neurol Psychiatr; 1986 Jan; 54(1):15-20. PubMed ID: 2868983
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic effects of bretazenil, a partial benzodiazepine agonist in acute schizophrenia--a study group report.
Delini-Stula A; Berdah-Tordjman D
J Psychiatr Res; 1996; 30(4):239-50. PubMed ID: 8905533
[TBL] [Abstract][Full Text] [Related]
12. Total and free plasma neuroleptic levels in schizophrenic patients.
Tang SW; Glaister J; Davidson L; Toth R; Jeffries JJ; Seeman P
Psychiatry Res; 1984 Dec; 13(4):285-93. PubMed ID: 6596586
[TBL] [Abstract][Full Text] [Related]
13. Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis.
Stevens A; Stevens I; Mahal A; Gaertner HJ
Pharmacopsychiatry; 1992 Nov; 25(6):273-7. PubMed ID: 1494594
[TBL] [Abstract][Full Text] [Related]
14. Relationship of serum haloperidol levels to clinical response in schizophrenic patients.
Magliozzi JR; Hollister LE; Arnold KV; Earle GM
Am J Psychiatry; 1981 Mar; 138(3):365-7. PubMed ID: 7468835
[TBL] [Abstract][Full Text] [Related]
15. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
[TBL] [Abstract][Full Text] [Related]
16. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
17. Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes.
Krakowski M; Czobor P; Volavka J
Psychiatry Res; 1997 Jun; 71(1):19-26. PubMed ID: 9247978
[TBL] [Abstract][Full Text] [Related]
18. Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report.
Volavka J; Cooper TB; Meisner M; Bitter I; Czobor P; Jaeger J
Psychopharmacol Bull; 1990; 26(1):13-7. PubMed ID: 2371368
[TBL] [Abstract][Full Text] [Related]
19. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
Davidson M; Kahn RS; Knott P; Kaminsky R; Cooper M; DuMont K; Apter S; Davis KL
Arch Gen Psychiatry; 1991 Oct; 48(10):910-3. PubMed ID: 1929760
[TBL] [Abstract][Full Text] [Related]
20. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
